BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
- Guggenheim 6th Annual Biotechnology Conference (New York, NY) – Markus Warmuth, M.D., Chief Executive Officer, to participate in fireside chat, February 7, 2024, at 1:30 p.m. ET.
- TD Cowen 44th Annual Health Care Conference (Boston, MA) – Filip Janku, M.D., Ph.D., Chief Medical Officer, to participate in corporate panel discussion, "Breast and Lung Cancer," March 6, 2024, ...